Femasys/$FEMY
1D1W1MYTD1Y5YMAX
Capital at risk
About Femasys
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
- Ticker
- $FEMY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 53
- Headquarters
- Suwanee, United States
- Website
- femasys.com
Femasys Metrics
BasicAdvanced
$21M
-
-$3.96
-2.09
-
Price and volume
Market cap
$21M
Beta
-2.09
52-week high
$4.78
52-week low
$2.02
Average daily volume
1.5M
Financial strength
Current ratio
2.144
Quick ratio
0.41
Long term debt to equity
1.071
Total debt to equity
1.188
Interest coverage (TTM)
-13.48%
Profitability
EBITDA (TTM)
-17.23
Gross margin (TTM)
60.95%
Net profit margin (TTM)
-511.77%
Operating margin (TTM)
-763.90%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-84.22%
Return on equity (TTM)
-424.97%
Valuation
Price to revenue (TTM)
3.285
Price to book
1.91
Price to tangible book (TTM)
1.96
Price to free cash flow (TTM)
-0.415
Free cash flow yield (TTM)
-240.78%
Free cash flow per share (TTM)
-6.116
Growth
Revenue change (TTM)
21.86%
Earnings per share change (TTM)
-76.67%
3-year revenue growth (CAGR)
24.34%
3-year earnings per share growth (CAGR)
-41.01%
Upcoming events
No upcoming events
Femasys News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.